Paolo A. Ascierto: From melanoma to kidney cancer, vaccine research is making significant strides
Paolo A. Ascierto, Director of Department Melanoma at Cancer Immunotherapy and Development Therapeutics, shared a paper David A. Braun and colleagues authored, on LinkedIn:
“From melanoma to kidney cancer (and beyond!), vaccine research is making significant strides.
A recent study published in Nature shows promising results: 9 patients with high-risk recurrent kidney cancer received a personalized cancer vaccine after surgery.
Beyond the absence of significant side effects, the vaccine successfully stimulated the production of a high number of immune cells specifically targeting the tumor. In other words, it appears to have done its job by “training” the immune system to recognize malignant cells.
This is yet another confirmation of the extraordinary potential of this immunotherapy approach, which we have been studying at Pascale Institute for over a year in a phase III trial for melanoma patients. It will take time to obtain definitive data, but what we have so far suggests we are on the right path.
The Nature study also opens up exciting new perspectives for a type of cancer that remains difficult to eradicate.”
A neoantigen vaccine generates antitumour immunity in renal cell carcinoma
Authors: David A. Braun et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023